Search clinical trials for: Active Psoriasis

Total 9949 results

Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety Study of SUNPG1623

Active Psoriatic Arthritis

United States
Johnson & Johnson Private Limited

Completed

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

Arthritis, Psoriatic | Spondylitis, Ankylosing

India
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
Can-Fite BioPharma

Completed

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Plaque Psoriasis

Israel, Serbia, Romania, Croatia, Bosnia and Herzegovina, Bulgaria, Canada, Moldova, Republic of, Poland
Amgen

Completed

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) (PALACE4)

Psoriatic Arthritis

United Kingdom, Belgium, United States, Canada, Australia, Taiwan, Czechia, Russian Federation, Hungary, Poland, Korea, Republic of, Italy, New Zealand, France, Bulgaria, Estonia, Romania, Lithuania
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Bristol-Myers Squibb

Completed

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (ASTRAEA)

Psoriatic Arthritis

Italy, South Africa, United States, Spain, Germany, Mexico, Israel, France, Greece, Canada, Brazil, Czechia, Peru, Poland, Argentina, Colombia, Chile
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Dr. Frank Behrens
Janssen-Cilag Ltd.

Completed

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA (MUST)

Psoriatic Arthritis

Germany
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Boehringer Ingelheim

Withdrawn

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Arthritis, Psoriatic
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Psoriatic Arthritis

United States, Puerto Rico
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Withdrawn

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
AbbVie
Boehringer Ingelheim

Completed

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Australia, Czechia, Hungary, Serbia, Slovakia, Estonia, Spain, Russian Federation, Lithuania, Bulgaria
AbbVie
Boehringer Ingelheim

Completed

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
UCB Biopharma S.P.R.L.

Completed

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (CIMPACT)

Psoriasis | Plaque Psoriasis

United States, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, United Kingdom
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Wake Forest University Health Sciences

Withdrawn

Iontophoresis in Psoriasis

Skin Diseases | Psoriasis | Psoriasis Vulgaris

United States
Xijing Hospital

Completed

Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis

Scalp Psoriasis

China
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) (Discover-1)

Arthritis, Psoriatic

United States, Canada, Taiwan, Hungary, Malaysia, Germany, Czechia, Korea, Republic of, Russian Federation, Spain, Australia, Ukraine, Poland
Can-Fite BioPharma

Completed

Trial of CF101 to Treat Patients With Psoriasis

Plaque Psoriasis

Israel, United States, Bulgaria, Romania
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

Chronic Plaque Psoriasis

Germany
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

United States, Germany, Spain, Poland, Romania, Canada, Russian Federation
Novartis Pharmaceuticals

Completed

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement (MAXIMISE)

Axial Psoratic Arthritis

Belgium, Israel, Spain, Switzerland, Greece, Italy, Bulgaria, Germany, Hungary, Estonia, United Kingdom, Poland, France, Czechia, Russian Federation, Romania, Ireland, Finland
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT-P2)

Psoriatic Arthritis

United States, France, Taiwan, Spain, Australia, Germany, United Kingdom, Poland, Czechia, Italy
Amgen

Completed

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE-1)

Psoriatic Arthritis

Spain, Canada, United States, Australia, Hungary, Poland, Austria, France, New Zealand, South Africa, Russian Federation, Germany, United Kingdom
Pfizer

Completed

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis (OPAL BALANCE)

Arthritis, Psoriatic

Belgium, United States, Canada, Spain, Australia, Taiwan, Czechia, Hungary, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Brazil, Bulgaria
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Amgen

Completed

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE 3)

Psoriatic Arthritis

United States, United Kingdom, Korea, Republic of, Spain, Germany, Switzerland, Slovakia, Australia, Poland, Russian Federation, Italy, Finland, Canada, Romania, Lithuania, France
Amgen

Completed

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE2)

Psoriatic Arthritis

United States, Italy, Belgium, France, Canada, Taiwan, United Kingdom, Czechia, Russian Federation, Hungary, Germany, Bulgaria, Estonia, South Africa, Poland, Spain
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
Eli Lilly and Company

Completed

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

Psoriatic Arthritis

Spain, Bulgaria, Czechia, Estonia, Mexico, Poland, Ukraine, United States, South Africa, Russian Federation, Slovakia, United Kingdom
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Moderate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's Disease

United States
Thync Global, Inc.
ethica Clinical Research Inc.

Unknown

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (FUTURE 4)

Arthritis, Psoriatic

United States, Italy, Germany, Australia, Belgium, Poland, Bulgaria, Russian Federation, Czechia, Canada, France, Sweden, United Kingdom
AbbVie
Boehringer Ingelheim

Completed

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic
Santalis Pharmaceuticals, Inc.
Derm Research, PLLC; ClinDatrix, Inc.; Clinical Trials of Texas, Inc.; Progressive... and other collaborators

Completed

A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc.; Fremantle Dermatology

Withdrawn

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults

Plaque Psoriasis

Australia
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Scalp Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis

United States

Search clinical trials for: Active Psoriasis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations